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(OSAS) and chronic obstructive pulmonary disease (COPD). Both OSAS and COPD are associated
with an increase in a variety of systemic inﬂammatory markers such as tumor necrosis factor-alpha
(TNF-a), interleukin-6 (IL-6), and C-reactive protein (CRP). Nasal continuous positive airway
pressure (CPAP) has been shown to improve overnight oxygenation in patients with overlap syn-
drome. It stands to reason that effective therapy for the sleep disorder would favorably affect
the inﬂammatory cascade.
Methods: Thirty-ﬁve patients with overlap syndrome were selected for the study. Tumor necrosis
factor-alpha, interleukin-6, and C-reactive protein were measured in patients with overlap syn-
drome before and after treatment with CPAP.
Results: Forced expiratory volume in 1st second (FEV1%) was 55.3 ± 4.58 before and 57.1 ± 4.78
after CPAP treatment (P 0.13). Forced vital capacity (FVC%) was 88.5 ± 3.26 before and
88.6 ± 3.13 after CPAP (P 0.97). FEV1/FVC%was 62.2 ± 4.14 before and 64.3 ± 4.24 after CPAPEar, Nose, Throat and Allied
evier B.V. All rights reserved.
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100 H.A.K.A. Mansour et al.(P 0.064) IL-6 was 3.13 ± 0.56 before and 1.87 ± 0.15 after CPAP (P< 0.0001). TNF-a was
7.4 ± 1.29 before and 4.77 ± 0.96 after CPAP (P< 0.0001). CRP was 0.83 ± 0.1 before and
0.44 ± 0.18 after CPAP (P< 0.0001).
Conclusion: There is statistically signiﬁcant difference in inﬂammatory markers levels before and
after CPAP treatment in patients with overlap syndrome. This suggests that inﬂammation in overlap
syndrome may be mediated by inﬂammatory markers in the form of CRP, IL-6, and TNF-a.
ª 2011 Egyptian Society of Ear, Nose, Throat and Allied Sciences.
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Obstructive sleep apnea syndrome (OSAS) is a disorder in
which patients exhibit repetitive episodes of partial or com-
plete obstruction of the upper airway during sleep, ultimately
leading to increased respiratory effort, oxyhemoglobin desatu-
ration, sleep fragmentation, and excessive daytime sleepiness.
Increasing evidence suggests that OSAS is associated with
hypertension and other cardiovascular diseases, metabolic
derangement and impaired glucose tolerance [1].
During an episode of apnea, the BP increases, imposing
shear stress on the vessel wall. This in turn leads to a cycle
of hypoxemia and re-oxygenation in the vascular endothelium
[2]. Inﬂammation evoked by endothelial injury plays a patho-
genic role in all stages of atherosclerosis, a progressive chronic
inﬂammatory disease of the arterial system [3]. In OSAS in-
tense local and systemic inﬂammation occurs and patients
present elevated inﬂammatory mediators such as tumor necro-
sis factor-alpha (TNF-a) and interleukin-6 [4,5]. Patients with
OSAS present also high levels of C-reactive protein (CRP),
which are related to disease severity [6,7].
Chronic obstructive pulmonary disease (COPD) is a condi-
tion of progressive deterioration of the respiratory system
characterized by the obstruction of pulmonary airways and de-
creased airﬂow. The airﬂow limitation is usually progressive
and associated to an abnormal inﬂammatory response of the
lungs to noxious particles or gases, primarily caused by ciga-
rette smoking [8]. COPD also produces other signiﬁcant sys-
temic consequences, including skeletal muscle dysfunction,
nutritional abnormalities, weight loss, cardiovascular, and ner-
vous system abnormalities [9].
In COPD patients several studies have shown that reduced
lung function is associated with an increase in a variety of sys-
temic inﬂammatory markers [10,11]. Compared to healthy
controls, COPD patients were found to have signiﬁcantly
raised levels of CRP, ﬁbrinogen, leukocytes, and TNF-a. All
of which indicate persistent systemic inﬂammation [12].
OSAS sometimes coexists with COPD. Flenley called this
combination ‘‘overlap syndrome’’ [13], the incidence of overlap
syndrome in COPD patients is 11.9% [14]. Nasal continuous
positive airway pressure (CPAP) has been shown to improve
overnight oxygenation in patients with overlap syndrome
[15], the greater hypoxia in the overlap syndrome might predis-
pose to atherosclerosis more than COPD and OSA alone,
although this is not yet proved [16]. Recent evidence of
systemic inﬂammation in COPD and sleep apnea, involving
C-reactive protein and interleukin-6, provide insight into po-
tential basic interactions between both disorders. Furthermore,
oxidative stress develops in each disorder, in addition to acti-
vation and/or dysfunction of circulating leukocytes. These
ﬁndings are clinically relevant since systemic inﬂammationmay contribute to the pathogenesis of cardiovascular diseases
and the cell/molecular pathways involved are similar to those
identiﬁed in COPD and sleep apnea [17]. Despite the high
prevalence of overlap syndrome, few data are available on its
pathophysiological and clinical consequences.
CPAP is very effective in treating patients with OSAS and
has been reported to reduce mortality in this disorder [18].
Because inﬂammatory mechanisms are active in OSAS, it
stands to reason that effective therapy for the sleep disorder
would favorably affect the inﬂammatory cascade [3]. Data
are particularly lacking regards the effect of CPAP on the
inﬂammatory mediators response in patients with overlap syn-
drome, so in this study, the effect of nasal CPAP treatment on
inﬂammatory mediators in patients with overlap syndrome
was assessed.
2. Methods
Thirty-ﬁve patients with overlap syndrome were selected for the
study. Patients diagnosed as moderate or severe obstructive
sleep apnea syndrome (OSAS) were recruited from ENT and
chest clinics between March 2007 and June 2010. Diagnosis of
OSAS was made by polysomnography. These patients were
subjected to pulmonary function tests and patients with ﬁxed
irreversible small airway obstruction indicating chronic obstruc-
tive pulmonary disease (COPD) were selected for the study.
Inclusion criteria included overlap syndrome patients with
moderate to severe OSAS combined with COPD who accepted
CPAP treatment. Subjects were excluded if they had heart dis-
ease, hypertension (BPP 140/90 in two separate measure-
ments), diabetes (fasting 120 mg/dl or post prandial blood
sugar 200 mg/dl), acute infection or previous CPAP treatment
of OSAS, or if there is change in body mass index (BMI) by
>5%. Patients with pure or mainly central apneas were
excluded from the study.
All subjects were assessed with history, physical examina-
tion, and anthropometric data (i.e., age, sex, BMI, neck cir-
cumference, waist circumference, and hip circumference)
along with daytime habits, such as smoking, physical exertion,
and nutritional habits were recorded, and chest radiograph,
ECG, and echocardiography were done. Body mass index
(BMI) was calculated (BMI = weight [kg]/height [m2]). All
subjects had simple spirometry, arterial blood gas measure-
ments, venipuncture for the measurement of CRP, TNF-a,
and IL-6. CRP was measured with a latex particle-enhanced
immunoturbidimetric assay, plasma levels of IL-6 and TNF-
a were measured with an enzyme-linked immunosorbent assay
(ELISA).
All subjects underwent an attendedovernight polysomnogra-
phy (Alice software) using a standardmontage of electroenceph-
alogram (EEG), electrooculogram (EOG), electromyogram
Table 2 The mean and standard deviation of the FEV1%,
FVC%, FEV1/FVC%, CRP, IL-6, and TNF-a before and
6 months after CPAP treatment.
Before CPAP After CPAP P value
FEV1% 55.3 ± 4.58 57.1 ± 4.78 0.13
FVC% 88.5 ± 3.26 88.6 ± 3.13 0.97
FEV1/FVC% 62.2 ± 4.14 64.3 ± 4.24 0.064
IL-6 3.13 ± 0.56 1.87 ± 0.15 <0.0001
TNF-a 7.4 ± 1.29 4.77 ± 0.96 <0.0001
CRP 0.83 ± 0.1 0.44 ± 0.18 <0.0001
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pulse oximetry, capnography, and airﬂow detected using com-
bined oronasal thermistors, Thoracic cage and abdominal
motion were recorded by inductive plethysmography. Apnea
hypopnea index (AHI) was calculated by dividing the total num-
ber of apneas and hypopneas to polysomnographically recorded
sleep time, while oxygen desaturation index (ODI) was calcu-
lated by dividing the total number of oxyhaemoglobin desatura-
tions P3% to polysomnographically recorded sleep time. The
patients underwent a second sleep study for CPAP titration.
Optimum CPAP pressure was deﬁned as the pressure value that
abolished all the respiratory events, arousals, and desaturation
episodes.
The patients were kept on simple nasal CPAP, its pressure
was adjusted according to the titration done in the second ses-
sion of polysomnography. Total hours on CPAP machine were
obtained from built in automatic time counter in the CPAP
machine. CPAP compliance was calculated retrograde by
dividing the total hours on CPAP counter over the total days
on CPAP machine.
A follow up spirometry and inﬂammatory mediators (CRP,
IL-6 and TNF-a) measurements were performed 6 months
after initiation of CPAP treatment.
Results for continuous variables are expressed as
mean ± SD. Paired samples t test was used for testing the dif-
ference of means before and after CPAP treatment. The
reported P-values are 2-tailed, and a P-value <0.05 was con-
sidered statistically signiﬁcant.
3. Results
The mean age of the patients in the study was 46.49 ± 5.15, 23
were males and 12 were females. Smoking status: 24 were cur-
rent smokers, ﬁve were nonsmokers, six were ex-smokers, the
mean body weight was 105.37 ± 12.36 and the mean body
mass index (BMI) was 37.70 ± 3.53. The mean of the neck cir-
cumference was 42.11 ± 1.94, the hip circumference wasTable 1 The demographic data and initial assessment param-
eters including polysomnographic assessment and CPAP
compliance.
Overlap syndrome patients (n= 35) Mean ± SD
Age (years) 46.49 ± 5.15
Gender (M/F) (23/12)
Body weight (Kg) 105.37 ± 12.36
BMI (Kg/m2) 37.70 ± 3.53
Neck circumference (cm) 42.114 ± 1.93
Waist circumference (cm) 120.23 ± 2.93
hip circumference (cm) 121.06 ± 2.60
WHR 0.9906 ± 0.01
Pa CO2 (mmHg) 38.811 ± 2.18
Polysomnography
ODI 54.7 ± 9.70
avSpO2 (%) 89.02 ± 2.74
AHI (/hour) 52.057 ± 9.21
CPAP compliance 4.311 ± 1.24
BMI, body mass index; WHR, Waist Hip Ratio; ODI, oxygen
desaturation index; avSpO2 (%), average oxygen saturation during
sleep (in pulse oxymetry); AHI, apnea hypopnea index; CPAP,
continuous positive airway pressure.121.06 ± 2.6 and the waist circumference was 120.23 ± 2.9.
Partial pressure of oxygen in arterial blood (Pa O2) mean
was 89 ± 2.7 and partial pressure of carbon dioxide in the
arterial blood (Pa CO2) mean was 38.8 ± 2.19.
During polysomnography the mean of the oxygen desatura-
tion index was 54.8 ± 9.7 and the apnea hypopnea index was
52.1 ± 9.2.
Table 1 shows the demographic data and initial assessment
parameters including polysomnographic assessment and
CPAP compliance.
Pulmonary function testing revealed that the patients were
in the stage II COPD (moderate COPD) as FEV1/FCV% and
FEV1% were 62.2 ± 4.14 and 55.3 ± 4.58, respectively,
before nCPAP and 64.3 ± 4.24 and 57.1 ± 4.78 at the end
of the study and Table 2 shows the mean and standard devia-
tion of the FEV1%, FVC%, FEV1/FVC%, IL-6, TNF-a, and
CRP before and 6 months after CPAP treatment.
Fig. 1 shows the IL-6 level before and after CPAP. Fig. 2
shows the TNF-a level before and after CPAP. Fig. 3 shows
the CRP level before and after CPAP.
The inﬂammatory mediators were studied before and after
6 months on CPAP and the percentage of change was calcu-
lated and compared with the patient compliance in terms of
average hours on CPAP, there was a statistical inverse relation
between compliance and CRP and TNF-a levels (r= 0.59,
P< 0.05) and (r= 0.49, P< 0.05), respectively Figs. 4 and
5. Whereas the IL-6 serum changes did not reach that signiﬁ-
cant value (r= 0.13, P> 0.05) Fig. 6.< 0.05
Figure 1 IL-6 level before (1) and after (2) CPAP (P value
<0.05).
< 0.05
Figure 2 TNF-a level before (1) and after (2) CPAP (P value
<0.05).
Figure 3 CRP level before (1) and after (2) CPAP (P value
<0.05).
Figure 4 Correlation between percent of decline of serum levels
of CRP and CPAP compliance showing statistical signiﬁcant
decline of the CRP with more hours on CPAP machine (r= 0.59,
P< 0.05).
Figure 5 Correlation between percent of decline of serum levels of
TNF-a and CPAP compliance showing statistical signiﬁcant decline
of the TNF-a with CPAP compliance (r= 0.49, P< 0.05).
Figure 6 Correlation between percent of decline of serum levels
of IL-6 and CPAP compliance showing non-signiﬁcant decline of
IL-6 after use of CPAP machine (r= 0.13, P> 0.05).
102 H.A.K.A. Mansour et al.4. Discussion
The present study has shown that the levels of inﬂammatory
mediators (CRP, IL-6 and TNF-a) were elevated in patients
with overlap syndrome and 6 months of CPAP therapyresulted in decreased level of these mediators. Despite the high
prevalence of overlap syndrome, few data are available on its
pathophysiological and clinical consequences.
Nocturnal oxygen desaturation is greater in patients with
the overlap syndrome than with COPD or OSAS alone [19]
and apnea-associated desaturation is more pronounced.
Daytime hypercapnia is also more common in overlap syn-
drome patients [20]. This more pronounced hypoxemia and
hypercapnia might result in greater cardiovascular morbidity
and mortality. Previous studies attempt to establish a link
between OSAS and inﬂammation by focusing on the mark-
ers TNF-a, IL-6, and CRP [21]. The acute-phase inﬂamma-
tory protein CRP (C-reactive protein) is produced by the
liver in response to IL-6 and contributes to atherosclerosis
by promoting adhesion molecule expression. CRP levels cor-
relate with future cardiovascular events [22], but the precise
role of CRP and IL-6 in the pathogenesis of cardiovascular
disease in these disorders is not fully established. Yokoe
et al. found that in OSAS, CRP, and IL-6 levels are elevated
[6].
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found a signiﬁcant decrease in the CRP levels after 6 months
of nCPAP therapy and this matches our results regards CRP
levels in patients with overlap syndrome, although in a study
by Ryan et al. [24] CRP levels did not show a signiﬁcant alter-
ation in 49 OSA patients after 6 weeks of CPAP use, and this
result may be attributed to the short term CPAP therapy. In
COPD, Torres et al. found that the IL-6 levels are increased
and IL-6 levels parallel CRP [25].
TNF-a is an inﬂammatory cytokine that has been found
elevated in patients with sleep apnea [26,27]. It is involved in
sleep regulation and has been positively correlated with exces-
sive daytime sleepiness, nocturnal sleep disturbance, and hy-
poxia [28,29]. TNF-a levels showed a signiﬁcant positive
correlation with apnea hypopnea index (AHI), and oxygen
desaturation index (ODI) [30].
Our results of high TNF-a levels in overlap syndrome
match with Takabatake et al. who found that systemic hypox-
emia contributes to TNF-a elevation in COPD [10], which is
particularly relevant in the overlap syndrome where hypox-
emia is more pronounced. Joppa et al concluded that circulat-
ing TNF-a level is higher in COPD patients with pulmonary
hypertension, who are also more hypoxemic [31]. Ryan and
his colleagues in 2006 in their study on patients with OSAS ob-
served that circulating TNF-a levels were elevated compared
with the control subjects, independent of obesity, and shown
to decline with CPAP therapy [30].
In the present study, we did not ﬁnd a statistically signiﬁ-
cant difference between the levels of FEV1%, FVC%, and
FEV1/FVC% before and after nasal CPAP therapy in pa-
tients with overlap syndrome, which matches with the results
of O’Brien and Whitman [14] study who found that treatment
of OSAS with CPAP therapy in patients with overlap syn-
drome may not lead to an improvement in the coexistent
COPD, on the contrary, a study done by De Miguel et al.
[32] on the effect of CPAP therapy on lung function in pa-
tients with overlap syndrome was evaluated and shown that
after 6 months of CPAP therapy, there were statistically sig-
niﬁcant increase in Pa O2, FEV1, and FVC, this may be
attributed to the nature of patients in Miguel study who were
mostly hypercapneic compared to eucapneic patients with
moderate COPD in the present study. Mansﬁeld and Naugh-
ton in their study on cases with severe COPD and sleep disor-
dered breathing found that there was an improvement in gas
exchange and FEV1 associated with a decrease incidence of
hospitalizations after use of maximal tolerable nCPAP during
sleep [33].
Our study had shown that there is an inverse relation be-
tween increased compliance to CPAP and the levels of the
inﬂammatory mediators (there is statistically signiﬁcant decline
in levels of TNF-a and CRP with increased compliance
whereas the IL-6 decline was not signiﬁcant), our results match
with the results in the study done by Steiropoulos and his col-
leagues in 2009 [34], who found signiﬁcant decline in the serum
levels of TNF-a in his 32 OSAS patients where there was good
compliance compared with less decline in the poor compliant
20 OSAS patients.
As COPD is an inﬂammatory airways disorder and OSAS
may act as an inﬂammatory stimulus. Thus, the improvement
in OSAS resulting from the application of CPAP may, in turn,
lead to an improvement in the coexistent COPD.5. Conclusion
There is statistically signiﬁcant difference in inﬂammatory
markers levels before and after CPAP treatment in patients
with overlap syndrome. This suggests that inﬂammation in
overlap syndrome may be mediated by inﬂammatory markers
in the form of CRP, IL-6, and TNF-a.6. Summary
 Overlap syndrome is a combination of OSAS and
COPD.
 Local and systemic inﬂammation may be mediated by
inﬂammatory mediators as TNF-a, IL-6, and CRP.
 Inﬂammatory markers levels decreases after CPAP
treatment in patients with overlap syndrome.
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